State Street Corp Buys 780,754 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

State Street Corp boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 17.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,143,534 shares of the company’s stock after buying an additional 780,754 shares during the period. State Street Corp owned approximately 5.05% of Intellia Therapeutics worth $105,700,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in NTLA. Blue Trust Inc. increased its holdings in shares of Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after acquiring an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares during the last quarter. Eastern Bank bought a new stake in Intellia Therapeutics during the 3rd quarter valued at about $41,000. Values First Advisors Inc. purchased a new position in Intellia Therapeutics in the third quarter worth about $54,000. Finally, First Horizon Advisors Inc. raised its holdings in Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after buying an additional 472 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NTLA stock opened at $12.90 on Monday. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -2.37 and a beta of 1.76. The firm has a fifty day moving average price of $16.13 and a 200-day moving average price of $20.60. Intellia Therapeutics, Inc. has a 1 year low of $12.47 and a 1 year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.38) EPS. Equities research analysts expect that Intellia Therapeutics, Inc. will post -5.12 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at $893,698.12. This represents a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 3.20% of the company’s stock.

Analyst Ratings Changes

NTLA has been the subject of several analyst reports. Wells Fargo & Company reduced their price target on shares of Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating for the company in a research report on Monday, November 18th. Royal Bank of Canada restated an “outperform” rating and issued a $54.00 price target on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Stifel Nicolaus lowered their price target on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. Robert W. Baird reduced their price objective on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, Barclays lowered their target price on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $54.94.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.